MetaVia's DA-1726 Clinical Trial Shows Significant Weight Loss of 21.2 lbs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Source: PRnewswire
- Significant Weight Loss: In a 54-day clinical trial, MetaVia's DA-1726 demonstrated an average weight reduction of 9.1% (21.2 lbs), indicating its substantial efficacy in obesity treatment and potential to become the most effective dual agonist on the market.
- Waist Circumference Reduction: Patients experienced an average waist circumference decrease of 9.8 cm (3.8 inches) by Day 54, reflecting not only the effectiveness of DA-1726 but also potentially providing a competitive edge in the obesity treatment sector.
- Improved Glycemic Control: DA-1726 resulted in a 12.3 mg/dL reduction in fasted glucose, showcasing its potential in enhancing metabolic health, particularly for the diabetes and prediabetes patient market.
- Liver Health Enhancement: The VCTE test indicated a 23.7% reduction in liver stiffness, demonstrating DA-1726's direct impact on liver health, which may support its future clinical applications.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on MTVA
Wall Street analysts forecast MTVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MTVA is 47.50 USD with a low forecast of 40.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.340
Low
40.00
Averages
47.50
High
55.00
Current: 2.340
Low
40.00
Averages
47.50
High
55.00
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MetaVia Inc. Closes $9.3 Million Public Offering to Advance Obesity Treatment Development
- Funding Size: MetaVia Inc. has successfully closed a public offering raising approximately $9.3 million, which includes 3,005,574 shares of common stock and 4,508,361 Series C and D warrants, with proceeds aimed at advancing the clinical development of obesity treatment drug DA-1726, demonstrating the company's ongoing commitment to cardiometabolic diseases.
- Warrant Details: The Series C and D warrants were issued at a price of $3.10 per share, are immediately exercisable, with Series C warrants valid for five years and Series D for two years, potentially yielding up to $28 million in future proceeds if fully exercised, enhancing the company's financial flexibility.
- Underwriter Role: Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for the offering, ensuring a smooth fundraising process and reflecting market confidence in MetaVia's future growth prospects.
- Clinical Trial Outlook: MetaVia is conducting a Phase 1b clinical trial for DA-1726, and positive data could trigger the call option for Series D warrants, further enhancing the company's competitive position in the obesity treatment market.
Continue Reading
MetaVia Inc. Closes $9.3 Million Public Offering to Advance Obesity Treatment Development
- Funding Amount: MetaVia Inc. has successfully closed a public offering raising approximately $9.3 million, which will be directed towards the clinical development of its obesity treatment drug DA-1726, demonstrating the company's ongoing commitment to cardiometabolic diseases.
- Shares and Warrants: The offering included 3,005,574 shares of common stock and 4,508,361 Series C and D warrants priced at $3.10 per share, indicating market confidence in its products and future potential.
- Future Revenue Potential: If the warrants are fully exercised, MetaVia could yield up to $28 million in future gross proceeds, providing substantial financial support for its research and operational needs.
- Underwriter Role: Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for this offering, showcasing its expertise and influence in the biotechnology financing sector.
Continue Reading